Edition:
United States

Editas Medicine Inc (EDIT.OQ)

EDIT.OQ on NASDAQ Stock Exchange Global Select Market

32.11USD
11:47am EDT
Change (% chg)

$1.56 (+5.11%)
Prev Close
$30.55
Open
$30.57
Day's High
$32.14
Day's Low
$30.45
Volume
98,901
Avg. Vol
276,300
52-wk High
$45.02
52-wk Low
$19.08

Latest Key Developments (Source: Significant Developments)

Editas Medicine Inc Files For Mixed Shelf Of Up To $150 Million – SEC Filing‍​
Monday, 12 Mar 2018 06:08pm EDT 

March 12 (Reuters) - Editas Medicine Inc ::EDITAS MEDICINE INC FILES FOR MIXED SHELF OF UP TO $150 MILLION – SEC FILING‍​.  Full Article

Editas Medicine Q4 Loss Per Share $0.84
Tuesday, 6 Mar 2018 04:01pm EST 

March 6 (Reuters) - Editas Medicine Inc ::EDITAS MEDICINE ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 RESULTS AND UPDATE.Q4 LOSS PER SHARE $0.84.EDITAS MEDICINE - EDIT-101 FOR LEBER CONGENITAL AMAUROSIS TYPE 10 ON TRACK FOR MID-2018 INVESTIGATIONAL NEW DRUG FILING.YEAR-END CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $329 MILLION EXPECTED TO FUND BUSINESS FOR AT LEAST 24 MONTHS.  Full Article

Editas Medicine Files For Potential Stock Shelf, Size Undisclosed - SEC Filing
Friday, 22 Dec 2017 04:52pm EST 

Dec 22 (Reuters) - Editas Medicine Inc ::EDITAS MEDICINE INC FILES FOR POTENTIAL STOCK SHELF, SIZE UNDISCLOSED - SEC FILING.  Full Article

Editas Medicine Announces Pricing Of $50 Mln Offering Of Common Stock
Wednesday, 6 Dec 2017 07:00am EST 

Dec 6 (Reuters) - Editas Medicine Inc ::EDITAS MEDICINE, INC., ANNOUNCES PRICING OF $50 MILLION OFFERING OF COMMON STOCK.EDITAS MEDICINE INC - ‍PRICING OF AN UNDERWRITTEN OFFERING OF 1.97 MILLION SHARES OF ITS COMMON STOCK​.  Full Article

Editas Medicine Announces Offering Of Common Stock
Tuesday, 5 Dec 2017 04:16pm EST 

Dec 5 (Reuters) - Editas Medicine Inc ::EDITAS MEDICINE, INC., ANNOUNCES OFFERING OF COMMON STOCK.EDITAS MEDICINE INC - INTENDS TO OFFER AND SELL $50 MILLION OF SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.  Full Article

Editas Medicine announces Q3 loss per share $0.64
Tuesday, 7 Nov 2017 04:03pm EST 

Nov 7 (Reuters) - Editas Medicine Inc ::Editas Medicine announces third quarter 2017 results and update.Q3 loss per share $0.64.Q3 earnings per share view $-0.60 -- Thomson Reuters I/B/E/S.Editas Medicine Inc - ‍cash, cash equivalents, and marketable securities at Sept. 30, 2017, were $295.7 million, compared to $199.9 million at Sept. 30, 2016​.  Full Article

Editas receives EMA's orphan medicinal product designation for EDIT-101
Tuesday, 26 Sep 2017 04:01pm EDT 

Sept 26 (Reuters) - Editas Medicine Inc :Editas Medicine receives EMA's orphan medicinal product designation for EDIT-101 for the treatment of LCA10.Editas Medicine plans to submit an investigational new drug (IND) application for EDIT-101 in mid-2018​.  Full Article

Editas Medicine Q2 loss per share $0.65
Wednesday, 9 Aug 2017 04:03pm EDT 

Aug 9 (Reuters) - Editas Medicine Inc :Editas Medicine announces second quarter 2017 results and update.Q2 loss per share $0.65.Q2 earnings per share view $-0.71 -- Thomson Reuters I/B/E/S.Qtrly collaboration and other research and development revenues $ 3.1 million versus. $ 3.4 million.  Full Article

Editas Medicine Q1 loss per share $0.85
Monday, 15 May 2017 04:01pm EDT 

May 15 (Reuters) - Editas Medicine Inc ::Editas Medicine announces first quarter 2017 results and update.Q1 loss per share $0.85.Q1 earnings per share view $-0.61 -- Thomson Reuters I/B/E/S.Editas Medicine Inc - target date for filing ind application for LCA10 program is being moved to middle of 2018.Editas Medicine Inc - research and development expenses were $19.0 million for quarter ended March 31, 2017, compared to $8.9 million for same period in 2016.  Full Article

Editas announces pricing of $90 million offering of common stock
Thursday, 16 Mar 2017 09:05pm EDT 

Editas Medicine Inc : Editas medicine, inc. Announces pricing of $90 million offering of common stock .Says offering of 4.00 million common shares priced at $22.50per share.  Full Article

BRIEF-Editas Medicine Reports Data Demonstrating Subretinal Injection Of Edit-101 Well-Tolerated In Non-Human Primates

* EDITAS MEDICINE REPORTS DATA DEMONSTRATING SUBRETINAL INJECTION OF EDIT-101 WELL-TOLERATED IN NON-HUMAN PRIMATES